Available company data, source links and archived checks for Alembic Pharmaceuticals Limited. Read each source and date: a past check is not a fresh review, and some earlier figures have incomplete source details.
Quarter ended 2026-06-30 · consolidated · Company filing
| Quarter | Revenue / income | YoY | Profit | YoY | Net margin | Source |
|---|---|---|---|---|---|---|
| Jun 2026 | Revenue: ₹2,150 cr | +25.7% | Net profit: ₹172 cr | +12.2% | 8.0% | Company filing source |
| Mar 2026 | Revenue: ₹1,848 cr | +4.4% | Net profit: ₹202 cr | +28.7% | 10.9% | Company filing source |
| Dec 2025 | Revenue: ₹1,876 cr | — | Net profit: ₹132 cr | — | 7.0% | Company filing source |
| Sep 2025 | Revenue: ₹1,910 cr | — | Net profit: ₹184 cr | — | 9.6% | Company filing source |
| Jun 2025 | Revenue: ₹1,711 cr | +9.5% | Net profit: ₹154 cr | +14.2% | 9.0% | Company filing source |
| Mar 2025 | Revenue: ₹1,770 cr | — | Net profit: ₹157 cr | — | 8.9% | Company filing source |
YoY means change from the same quarter a year earlier. — means no comparable figure is available. Older entries with incomplete source details have not been revalidated under the current checks.
APLLTD: consolidated net profit changed by 12.2% in the quarter ending 30 June 2026, compared with the quarter ending 2025-06-30.
APLLTD: consolidated net profit for the quarter ending 30 June 2026 was ₹172.36 crore.
APLLTD: consolidated revenue changed by 25.7% in the quarter ending 30 June 2026, compared with the quarter ending 2025-06-30.
APLLTD: consolidated revenue for the quarter ending 30 June 2026 was ₹2,149.77 crore.
Alembic Pharmaceuticals Limited Rahul Jeewani: Okay, sir. Sure. And coming back to margins for FY27, at one point in time, you indicated that the operating leverage on the base business would get offset by the investments on the US branded side. And at another point in call, you referred to high-teens margins as well. So I'm a bit confused in terms of what's margin guidance for FY27? Pranav Amin: Sure. So see, the margin guidance is intact in the sense that let me reiterate the guidance again. So we did about 16% margins in FY26, and we believe that the margins -- the underlying core margins will improve. And my comment was about the core margin improving to high-teens and which will partially get offset by the margin dilution from US branded business, which we said will be about 150 basis points, right? So that remains intact. And we are seeing the operating leverage playing out in the first quarter as well on the core business, and which we believe will continue to happen in the rest of the year -- rest of the quarters as well as we see better utilization and good volume-driven growth across US and exUS markets. Does that clarify, Rahul? Rahul Jeewani: Sure, sir. So, versus FY26 levels would we stay largely flat on a full year basis.
Keep its available filings, dated fact checks and disclosure alerts together. Your saved country sets your market and its research schedule.
Start free — first week on us →Company data and archived claim checks are shown with available sources. Check the source and date before relying on a figure. This is not investment advice or a recommendation. Investment in securities markets is subject to market risks. Research on this site is produced with substantial use of AI. Terms, disclosures and grievances